Related Experiment Video
Updated: May 16, 2026
Experimental Strategies to Bridge Large Tissue Gaps in the Injured Spinal Cord after Acute and Chronic Lesion
Published on: April 5, 2016
From bench to beside to cure spinal cord injury: lost in translation?
1Spinal Cord Injury Center, Heidelberg University Hospital, Heidelberg, Germany.
Abstract:
Despite intense efforts to overcome the inhospitable milieu for axonal regeneration within the damaged spinal cord an evidence-based repair strategy promoting relevant functional improvement is still not available for spinal cord injured individuals. Nevertheless, several preclinical axonal regenerative strategies were developed all the way to phase I/II clinical trials, which have recently been terminated. The aim of this chapter is to critically review translated preclinical treatment strategies with respect to their conformity with previously published guidelines and requirements for preclinical studies leading to clinical trials in human subjects with spinal cord injury (SCI). Cell-based strategies (macrophage and embryonic stem cell grafting) and the administration of C3 transferase inhibitors and anti-Nogo-A antibodies were investigated. Overall, these four approaches comply with preclinical quality standards to varying degree. For future preclinical analyses, several additive components such as defined criteria for robustness of observed effects, a clear confirmation of underlying structural mechanisms, and the implementation of appropriate preclinical rehab approaches should be considered in order to increase the quality and consequently the likelihood of respective therapeutic strategies to succeed in human individuals suffering from SCI.
Insights
Effective spinal cord injury repair strategies remain elusive. Preclinical treatments, including cell therapies and antibody treatments, show variable adherence to quality standards, necessitating improved preclinical research for future clinical success.
Area of Science:
- Neuroscience
- Regenerative Medicine
- Clinical Trials
Background:
- Spinal cord injury (SCI) presents a significant challenge for axonal regeneration due to the inhibitory environment.
- Despite numerous preclinical strategies, no evidence-based repair strategy has led to functional improvement in SCI individuals.
- Recent Phase I/II clinical trials for SCI regenerative strategies have been terminated.
Purpose of the Study:
- To critically review preclinical axonal regenerative strategies for spinal cord injury (SCI).
- To assess the conformity of these strategies with established preclinical study guidelines for clinical translation.
- To identify areas for improvement in preclinical research to enhance therapeutic success in SCI patients.
Main Methods:
- Review of translated preclinical treatment strategies for SCI.
- Investigation of cell-based strategies: macrophage and embryonic stem cell grafting.
- Analysis of pharmacological interventions: C3 transferase inhibitors and anti-Nogo-A antibodies.
Main Results:
- The reviewed preclinical strategies (cell-based therapies, C3 transferase inhibitors, anti-Nogo-A antibodies) demonstrated varying degrees of compliance with preclinical quality standards.
- None of the investigated approaches fully met all established guidelines for preclinical studies aiming for clinical trials in SCI.
Conclusions:
- Future preclinical studies for SCI regeneration require defined criteria for effect robustness and mechanistic confirmation.
- Integration of appropriate preclinical rehabilitation approaches is crucial for improving the quality of research.
- Enhancing preclinical research quality is essential to increase the likelihood of therapeutic strategies succeeding in human SCI patients.
Related Concept Videos
01:14Spinal Cord Injury ll: Pathophysiology
01:25Secondary Spinal Cord Injury llI: Pathophysiology
01:26Spinal Cord